繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Itamar Medical sees Q3 as high as $11M, above consensus

2020-10-13 18:20

Itamar Medical(NASDAQ:ITMR)reports preliminary results for Q3 and revenue guidance for FY 2020.

Total revenue for Q3 is expected to be $10.7M to $11M, an increase of 32% to 36% compared to Q3 2019 and above consensus of $9.49M.

Q3 U.S. WatchPAT revenue of $8.6M to $8.9M.

On April 13, 2020, Itamar Medical withdrew its FY 2020 revenue guidance due to COVID-19 uncertainties. The Company is reinstating its full year revenue guidance to a range of $39.5M to $40.5M, growth of approx. 26% to 29% Y/Y, higher than the average analyst estimate of $38.38M.

The Company expects to issue full third quarter 2020 results in mid-November.

Wall Street Rating is Very Bullish with price target of $26.76 whereas Quant Rating is Neutral.

Click to subscribe to real-time analytics on ITMR

Now read:Zynex slips 21% on reporting Q3 orders and lowering revenue guidance »

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。